News

A common drug shows promise for patients with liver disease
A new study reveals that dapagliflozin, a common diabetes medication, could significantly improve conditions like metabolic ...
News Medical on MSN7h
Diabetes drug shows benefits for patients with liver disease
The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...
The BMJ19h
Dapagliflozin and metabolic dysfunction-associated steatohepatitis
Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...
MedPage Today on MSN20h
SGLT2 Inhibitor Shows Promise as MASH Treatment
Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...
GB News on MSN5h
Dietitian shares 2 fatty liver signs seen in clients as 15 million unknowingly live with 'aggressive form' of disease
More than 15 million people across the US, UK, Germany and France are unknowingly living with metabolic ...
89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...
Parade on MSN23h
What Happens When Your Liver Enzymes Are Too High?
Why are elevated liver enzymes a red flag that doctors say shouldn’t be ignored? Keep reading to find out. 🩺 SIGN UP for ...
The Chronicle13h
Former FDA Commissioner says MAHA report has ‘the right diagnosis’ but ‘the wrong treatment’
The Chronicle spoke with Duke alumnus and professor Robert Califf about the recent “Make America Healthy Again” report and ...